Skip to main content

Drug Interactions between Nimbex and polymyxin b

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

polymyxin B sulfate cisatracurium

Applies to: polymyxin b and Nimbex (cisatracurium)

GENERALLY AVOID: Polymyxin B may prolong apnea and respiratory paralysis after use of neuromuscular blocking agents. The mechanism may be related to decreased intracellular potassium or decreased ionized serum calcium. Intravenous calcium administration may be helpful in reversing the paralysis.

MANAGEMENT: This combination should be avoided unless the benefit outweighs the risk. Patients should be closely monitored for signs of extended neuromuscular blockade.

References (3)
  1. Levine RA, Beiber MP, Forte FA, et al. (1969) "Polymyxin B-induced respiratory paralysis reversed by intravenous calcium chloride." J Mt Sinai Hosp N Y, 36, p. 380-7
  2. Fogdall RP, Miller RD (1974) "Prolongation of a pancuronium-induced neuromuscular blockade by polymyxin B." Anesthesiology, 40, p. 84-7
  3. (2001) "Product Information. Raplon (rapacuronium)." Organon

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer